| GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials.Sleep Breath | Pooled analysis | 2026 |
| Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis.Clin Obes | Pooled analysis | 2026 |
| GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.Drugs | Pooled analysis | 2026 |
| Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.Clin Obes | Pooled analysis | 2026 |
| Glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.Headache | Pooled analysis | 2026 |
| Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.J Endocrinol Invest | Pooled analysis | 2026 |
| Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.J Am Heart Assoc | Pooled analysis | 2026 |
| Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.PeerJ | Pooled analysis | 2026 |
| Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.Endocrinol Diabetes Metab | Pooled analysis | 2026 |
| Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.Endocrinol Diabetes Metab | Pooled analysis | 2026 |
| Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.Diabetes Res Clin Pract | Pooled analysis | 2026 |
| Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.Obesity (Silver Spring) | Pooled analysis | 2026 |
| Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.Clin Res Cardiol | Pooled analysis | 2026 |
| Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2026 |
| Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.Endocrine | Pooled analysis | 2026 |
| Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.Ann Intern Med | Pooled analysis | 2026 |
| The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.Diabetes Obes Metab | Pooled analysis | 2026 |
| Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials.Can J Diabetes | Pooled analysis | 2026 |
| Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.Endocrine | Pooled analysis | 2026 |
| Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.BMJ | Pooled analysis | 2026 |
| Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.Diabetes Metab Syndr | Pooled analysis | 2026 |
| Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.Endocrinol Diabetes Metab | Pooled analysis | 2026 |
| Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.Endocrinol Diabetes Metab | Pooled analysis | 2026 |
| Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis.Diabetes Res Clin Pract | Pooled analysis | 2026 |
| Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.Diabetes Obes Metab | Pooled analysis | 2026 |
| Long-term effects of weight-reducing drugs in people with hypertension.Cochrane Database Syst Rev | Pooled analysis | 2026 |
| GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies.Diabetes Res Clin Pract | Pooled analysis | 2026 |
| Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.Obesity (Silver Spring) | Pooled analysis | 2026 |
| Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.Pancreatology | Pooled analysis | 2026 |
| Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials.Intern Emerg Med | Pooled analysis | 2026 |
| Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Diabetes Obes Metab | Pooled analysis | 2026 |
| GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.Diabetes Obes Metab | Pooled analysis | 2026 |
| Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.Dis Mon | Pooled analysis | 2026 |
| Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis.Expert Opin Drug Saf | Pooled analysis | 2026 |
| Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.J Transl Med | Pooled analysis | 2026 |
| Efficacy of tirzepatide in glycemic control and weight management in adults with type 2 diabetes: a systematic review and meta-analysis of real-world studies.Postgrad Med J | Pooled analysis | 2026 |
| Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis.Eur J Prev Cardiol | Pooled analysis | 2026 |
| Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis.Int J Mol Sci | Pooled analysis | 2026 |
| Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.Expert Rev Endocrinol Metab | Pooled analysis | 2026 |
| Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Hum Psychopharmacol | Pooled analysis | 2026 |
| Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.Adv Ther | Pooled analysis | 2026 |
| Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.Diabetes Obes Metab | Pooled analysis | 2026 |
| Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.Diabetes Obes Metab | Pooled analysis | 2026 |
| Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials.Diabetes Obes Metab | Pooled analysis | 2026 |
| Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.Diabetes Obes Metab | Pooled analysis | 2026 |
| Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists: A Network Meta-Analysis of Randomized Controlled Trials.Obesity (Silver Spring) | Pooled analysis | 2026 |
| GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.BMC Cardiovasc Disord | Pooled analysis | 2026 |
| The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.BMC Med | Pooled analysis | 2026 |
| GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.Medicine (Baltimore) | Pooled analysis | 2026 |
| Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.JAMA Netw Open | Pooled analysis | 2026 |
| Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.Obes Res Clin Pract | Pooled analysis | 2026 |
| Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis.Respir Med | Pooled analysis | 2026 |
| Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta-Analysis of Real-World Studies.Endocr Pract | Pooled analysis | 2026 |
| Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis.Cardiovasc Diabetol | Pooled analysis | 2026 |
| Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.BMC Med | Pooled analysis | 2026 |
| Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide.J Diabetes | Pooled analysis | 2026 |
| Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis.Obesity (Silver Spring) | Pooled analysis | 2026 |
| Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH).Diabetes Obes Metab | Pooled analysis | 2026 |
| Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.Ann Intern Med | Pooled analysis | 2026 |
| GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis.Metabolism | Pooled analysis | 2026 |
| Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.Rev Endocr Metab Disord | Pooled analysis | 2026 |
| Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials.Endocrine | Pooled analysis | 2026 |
| Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.Diabetes Obes Metab | Pooled analysis | 2026 |
| Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.Diabetes Obes Metab | Pooled analysis | 2026 |
| Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.Neurol Sci | Pooled analysis | 2025 |
| Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.Medicine (Baltimore) | Pooled analysis | 2025 |
| The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis.Addict Sci Clin Pract | Pooled analysis | 2025 |
| Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis.Diabetes Res Clin Pract | Pooled analysis | 2025 |
| Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis.Obes Surg | Pooled analysis | 2025 |
| Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.Int J Obes (Lond) | Pooled analysis | 2025 |
| Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.Clin Obes | Pooled analysis | 2025 |
| Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.Hepatology | Pooled analysis | 2025 |
| The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials.J Hematol Oncol | Pooled analysis | 2025 |
| Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis.Biomolecules | Pooled analysis | 2025 |
| Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.J Am Coll Cardiol | Pooled analysis | 2025 |
| Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis.J Crohns Colitis | Pooled analysis | 2025 |
| Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.Obesity (Silver Spring) | Pooled analysis | 2025 |
| GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials.Int J Cardiol | Pooled analysis | 2025 |
| Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Obes Rev | Pooled analysis | 2025 |
| Tirzepatide for adults living with obesity.Cochrane Database Syst Rev | Pooled analysis | 2025 |
| Semaglutide for adults living with obesity.Cochrane Database Syst Rev | Pooled analysis | 2025 |
| GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis.Langenbecks Arch Surg | Pooled analysis | 2025 |
| Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis.Diabetes Metab Res Rev | Pooled analysis | 2025 |
| A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.Nat Med | Pooled analysis | 2025 |
| Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.Int J Obes (Lond) | Pooled analysis | 2025 |
| Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.J Clin Endocrinol Metab | Pooled analysis | 2025 |
| Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Endocrinol Diabetes Metab | Pooled analysis | 2025 |
| Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.Eur J Neurol | Pooled analysis | 2025 |
| Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in China.Diabetes Obes Metab | Pooled analysis | 2025 |
| Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.Diabetes Obes Metab | Pooled analysis | 2025 |
| Comparative Effectiveness of Glucagon-like Peptide-1- Receptor Agonists in Patients With Heart Failure With Preserved or Minimally Reduced Ejection Fraction: A Comprehensive Bayesian Network Meta-Analysis and Network Meta-Regression.Endocr Pract | Pooled analysis | 2025 |
| Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.Acta Diabetol | Pooled analysis | 2025 |
| Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.BMJ | Pooled analysis | 2025 |
| Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.Sleep Med Rev | Pooled analysis | 2025 |
| Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.Obes Rev | Pooled analysis | 2025 |
| Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.J Obes | Pooled analysis | 2025 |
| Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2025 |
| Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis.Sci Rep | Pooled analysis | 2025 |
| Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.Diabetes Obes Metab | Pooled analysis | 2025 |
| Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.Diabetes Technol Ther | Pooled analysis | 2025 |
| Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.J Am Coll Cardiol | Pooled analysis | 2025 |
| Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.Obes Surg | Pooled analysis | 2025 |
| Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.Endocrinol Diabetes Metab | Pooled analysis | 2025 |
| Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis.Sleep | Pooled analysis | 2025 |
| Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.J Diabetes | Pooled analysis | 2025 |
| Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: A systematic review and network meta-analysis.Diabetes Res Clin Pract | Pooled analysis | 2025 |
| Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.Ann Saudi Med | Pooled analysis | 2025 |
| Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.Obes Surg | Pooled analysis | 2025 |
| Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.Metabolism | Pooled analysis | 2025 |
| Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis.Endocr Pract | Pooled analysis | 2025 |
| Role of Incretin Mimetics in Cardiovascular Outcomes and Other Classical Cardiovascular Risk Factors beyond Obesity and Diabetes Mellitus in Nondiabetic Adults with Obesity: a Meta-analysis of Randomized Controlled Trials.Am J Cardiovasc Drugs | Pooled analysis | 2025 |
| Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2025 |
| Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.Endocrinol Metab (Seoul) | Pooled analysis | 2025 |
| Dose-Response Relationship of Glucagon-like Peptide-1 Receptor Agonists on HbA1c and Body Weight in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.Endocr Pract | Pooled analysis | 2025 |
| Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.J Diabetes Investig | Pooled analysis | 2025 |
| Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.BMC Endocr Disord | Pooled analysis | 2024 |
| Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.Metabolism | Pooled analysis | 2024 |
| Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.Int J Obes (Lond) | Pooled analysis | 2024 |
| Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials.Int J Clin Pharm | Pooled analysis | 2024 |
| Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.Endocrine | Pooled analysis | 2024 |
| Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.Diabetes Obes Metab | Pooled analysis | 2024 |
| Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.Eur Stroke J | Pooled analysis | 2024 |
| Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.Diabetes Res Clin Pract | Pooled analysis | 2024 |
| Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.Diabetologia | Pooled analysis | 2024 |
| Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.Cochrane Database Syst Rev | Pooled analysis | 2024 |
| Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.Ann Intern Med | Pooled analysis | 2024 |
| Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.Obes Rev | Pooled analysis | 2024 |
| The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines.J Endocrinol | Pooled analysis | 2024 |
| Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis.Obesity (Silver Spring) | Pooled analysis | 2024 |
| Evidence that tirzepatide protects against diabetes-related cardiac damages.Cardiovasc Diabetol | Pooled analysis | 2024 |
| Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis.Diabetes Obes Metab | Pooled analysis | 2024 |
| Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.Endocr Pract | Pooled analysis | 2024 |
| Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.Diabetes Obes Metab | Pooled analysis | 2024 |
| Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.Front Public Health | Pooled analysis | 2024 |
| Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.BMJ | Pooled analysis | 2024 |
| Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.Pharmacol Res | Pooled analysis | 2024 |
| Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.Diabetes Obes Metab | Pooled analysis | 2024 |
| Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.Diabetes Obes Metab | Pooled analysis | 2023 |
| Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity.Eur J Prev Cardiol | Pooled analysis | 2023 |
| Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis.Medicine (Baltimore) | Pooled analysis | 2023 |
| Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2023 |
| Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.Int J Obes (Lond) | Pooled analysis | 2023 |
| Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.Front Endocrinol (Lausanne) | Pooled analysis | 2023 |
| Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.Eur Rev Med Pharmacol Sci | Pooled analysis | 2023 |
| Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.Clin Ther | Pooled analysis | 2023 |
| Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.Int J Obes (Lond) | Pooled analysis | 2023 |
| Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review.Intern Med J | Pooled analysis | 2023 |
| A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy-A Systematic Review and Meta-Analysis.Int J Mol Sci | Pooled analysis | 2023 |
| Weight loss efficiency and safety of tirzepatide: A Systematic review.PLoS One | Pooled analysis | 2023 |
| Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.Diabetes Obes Metab | Pooled analysis | 2023 |
| Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.BMJ | Pooled analysis | 2023 |
| Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.Obes Rev | Pooled analysis | 2023 |
| Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.Diabetes Metab Syndr | Pooled analysis | 2022 |
| Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2022 |
| Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.Diabetologia | Pooled analysis | 2022 |
| Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.Diabetes Metab Syndr | Pooled analysis | 2022 |
| Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.Nat Med | Pooled analysis | 2022 |
| SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.Obesity (Silver Spring) | Random groups | 2026 |
| Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analyses.Sleep | Random groups | 2026 |
| Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.Diabetes Care | Random groups | 2026 |
| Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis Rheumatol | Random groups | 2026 |
| Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI.Liver Int | Random groups | 2026 |
| Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials.Diabetes Obes Metab | Random groups | 2026 |
| Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.J Clin Sleep Med | Random groups | 2026 |
| Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.PLoS One | Random groups | 2026 |
| Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.J Am Coll Cardiol | Random groups | 2026 |
| Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.Diabetes Obes Metab | Random groups | 2026 |
| Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study.Diabetes Obes Metab | Random groups | 2026 |
| Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.Cardiovasc Revasc Med | Random groups | 2026 |
| Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).Med | Random groups | 2026 |
| Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.Nat Med | Random groups | 2026 |
| Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial.Ann Intern Med | Random groups | 2026 |
| Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.JAMA Dermatol | Random groups | 2026 |
| Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Nat Med | Random groups | 2026 |
| A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.Lancet Diabetes Endocrinol | Random groups | 2026 |
| Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.Am J Med | Random groups | 2026 |
| Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.Lancet | Random groups | 2026 |
| Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.Curr Med Res Opin | Random groups | 2026 |
| Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1.J Endocrinol Invest | Random groups | 2026 |
| Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.JAMA Cardiol | Random groups | 2026 |
| Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.Diabetologia | Random groups | 2026 |
| Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease.Curr Med Res Opin | Random groups | 2026 |
| ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition.Mol Metab | Random groups | 2026 |
| Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.BMJ Open Diabetes Res Care | Random groups | 2026 |
| Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.Nat Commun | Random groups | 2026 |
| [SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes].Rev Med Liege | Random groups | 2026 |
| Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.Obesity (Silver Spring) | Random groups | 2026 |
| Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring) | Random groups | 2026 |
| Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.Ann Rheum Dis | Random groups | 2026 |
| Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.Nat Med | Random groups | 2026 |
| Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.Diabetes Obes Metab | Random groups | 2026 |
| Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.JAMA Intern Med | Random groups | 2026 |
| Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.Mol Metab | Random groups | 2026 |
| Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.Diabetes Care | Random groups | 2026 |
| Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.Diabetes Obes Metab | Random groups | 2026 |
| People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.Obesity (Silver Spring) | Random groups | 2026 |
| Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.N Engl J Med | Random groups | 2025 |
| Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet Diabetes Endocrinol | Random groups | 2025 |
| Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.Sleep Med | Random groups | 2025 |
| Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide.Diabetes Care | Random groups | 2025 |
| Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.Diabetes Obes Metab | Random groups | 2025 |
| Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.Diabetes Obes Metab | Random groups | 2025 |
| A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide.Clin Pharmacol Ther | Random groups | 2025 |
| In adults with obesity but without type 2 diabetes, tirzepatide increased weight loss at 72 wk compared with semaglutide.Ann Intern Med | Random groups | 2025 |
| Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.Diabetes Obes Metab | Random groups | 2025 |
| Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4.Obesity (Silver Spring) | Random groups | 2025 |
| Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | Random groups | 2025 |
| Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.Nat Med | Random groups | 2025 |
| Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.Sleep Med | Random groups | 2025 |
| Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4.Diabetes | Random groups | 2025 |
| Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.J Am Coll Cardiol | Random groups | 2025 |
| Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.Front Endocrinol (Lausanne) | Random groups | 2025 |
| Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.Obesity (Silver Spring) | Random groups | 2025 |
| Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.Diabetes Care | Random groups | 2025 |
| Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.Diabetes Obes Metab | Random groups | 2025 |
| Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.Nat Med | Random groups | 2025 |
| Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.Diabetes Obes Metab | Random groups | 2025 |
| Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.Ann Intern Med | Random groups | 2025 |
| Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.Diabetes Obes Metab | Random groups | 2025 |
| Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.Diabetes Obes Metab | Random groups | 2025 |
| Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.Diabetes Obes Metab | Random groups | 2025 |
| Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.J Am Coll Cardiol | Random groups | 2025 |
| Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J Med | Random groups | 2025 |
| Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN study.Obesity (Silver Spring) | Random groups | 2025 |
| Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.Diabetes Obes Metab | Random groups | 2025 |
| Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial.Lancet Diabetes Endocrinol | Random groups | 2025 |
| Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 Study.Adv Ther | Random groups | 2025 |
| Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.Diabetes Obes Metab | Random groups | 2025 |
| Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.Clin Obes | Random groups | 2025 |
| Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.J Am Coll Cardiol | Random groups | 2025 |
| Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.Cell Metab | Random groups | 2025 |
| Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.Ann Intern Med | Random groups | 2025 |
| Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials.Diabetes Care | Random groups | 2025 |
| Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.Lancet Diabetes Endocrinol | Random groups | 2025 |
| Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes Obes Metab | Random groups | 2025 |
| Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial.J Diabetes Investig | Random groups | 2025 |
| The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose-escalation Phase I study.Diabetes Obes Metab | Random groups | 2025 |
| Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.Diabetes Obes Metab | Random groups | 2025 |
| Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS.J Clin Endocrinol Metab | Random groups | 2025 |
| Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.Circulation | Random groups | 2025 |
| Tirzepatide for Obesity Treatment and Diabetes Prevention.N Engl J Med | Random groups | 2025 |
| Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.Diabetes Obes Metab | Random groups | 2025 |
| Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.Diabetes Care | Random groups | 2025 |
| Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.J Am Coll Cardiol | Random groups | 2025 |
| Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.Nat Med | Random groups | 2025 |
| Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.Diabetes Obes Metab | Random groups | 2025 |
| Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.N Engl J Med | Random groups | 2025 |
| Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.J Clin Endocrinol Metab | Random groups | 2024 |
| Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.Diabetes Obes Metab | Random groups | 2024 |
| Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.N Engl J Med | Random groups | 2024 |
| Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.Heart | Random groups | 2024 |
| Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.JAMA | Random groups | 2024 |
| Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.N Engl J Med | Random groups | 2024 |
| Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.Aliment Pharmacol Ther | Random groups | 2024 |
| Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).J Clin Endocrinol Metab | Random groups | 2024 |
| Characterization of tirzepatide-treated patients achieving different glycemic control levels in SURPASS-AP-Combo.Obesity (Silver Spring) | Random groups | 2024 |
| Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.Diabetes Res Clin Pract | Random groups | 2024 |
| Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.Diabetes Care | Random groups | 2024 |
| Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials.Diabetes Care | Random groups | 2024 |
| Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.Diabetes Obes Metab | Random groups | 2024 |
| Tirzepatide and exercise training in obesity.Clin Hemorheol MicrocircRetracted | Random groups | 2024 |
| Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.Diabetes Obes Metab | Random groups | 2024 |
| Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.Diabetes Obes Metab | Random groups | 2024 |
| Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.Diabetes Obes Metab | Random groups | 2023 |
| Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.JAMA | Random groups | 2023 |
| Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.Nat Med | Random groups | 2023 |
| Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial.Int J Obes (Lond) | Random groups | 2023 |
| A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes.Adv Ther | Random groups | 2023 |
| Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.Nat Med | Random groups | 2023 |
| Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.Diabetes Care | Random groups | 2023 |
| Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.Diabetes Obes Metab | Random groups | 2023 |
| Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).Diabetes Obes Metab | Random groups | 2023 |
| Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.Lancet Diabetes Endocrinol | Random groups | 2022 |
| Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.Lancet Diabetes Endocrinol | Random groups | 2022 |
| Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.Lancet Diabetes Endocrinol | Random groups | 2022 |
| [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].Rev Med Suisse | Random groups | 2022 |
| Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.Lancet Diabetes Endocrinol | Random groups | 2022 |
| Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.Lancet Diabetes Endocrinol | Random groups | 2022 |
| Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.Lancet Diabetes Endocrinol | Random groups | 2022 |
| Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.JAMA | Random groups | 2022 |
| A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.Diabetes Obes Metab | Random groups | 2022 |
| Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.J Clin Endocrinol Metab | Random groups | 2022 |
| Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.Lancet | Random groups | 2021 |
| Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med | Random groups | 2021 |
| Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.Lancet | Random groups | 2021 |
| Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.J Clin Endocrinol Metab | Random groups | 2021 |
| The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.Diabetes Obes Metab | Random groups | 2020 |
| Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.Diabetes Care | Random groups | 2020 |
| Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.Diabetes Obes Metab | Random groups | 2020 |
| Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.J Med Econ | No random groups | 2026 |
| Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.Diabetologia | No random groups | 2025 |
| Beyond Weight Loss: Comparative Effects of Tirzepatide Plus Low-Energy Ketogenic Versus Low-Calorie Diet on Hepatic Steatosis and Stiffness in MASLD.Nutrients | No random groups | 2025 |
| Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys.Eur J Pharm Sci | No random groups | 2024 |
| 5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.Diabetes Obes Metab | No random groups | 2024 |
| Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.Diabetes Care | No random groups | 2023 |
| Tirzepatide to treat obesity: phase III results.Nat Rev Gastroenterol Hepatol | No random groups | 2022 |
| Tirzepatide Trial Demonstrates Substantial Weight Loss.JAMA | No random groups | 2022 |
| The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.Diabetes Obes Metab | No random groups | 2022 |
| Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.Lancet | No random groups | 2021 |
| Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.Clin Pharmacokinet | No random groups | 2021 |
| Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study.Int J Cardiol | Group followed over time | 2026 |
| Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity.J Diabetes Complications | Group followed over time | 2026 |
| Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study.J Diabetes Complications | Group followed over time | 2026 |
| Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis.Diabetes Obes Metab | Group followed over time | 2026 |
| Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: A prospective study.Clin Nutr ESPEN | Group followed over time | 2026 |
| Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide.Diabetes Metab Res Rev | Group followed over time | 2026 |
| Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.J Clin Endocrinol Metab | Group followed over time | 2026 |
| Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.BMJ | Group followed over time | 2026 |
| Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study.Hepatol Int | Group followed over time | 2026 |
| Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety.Obes Surg | Group followed over time | 2026 |
| Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study.Diabetes Obes Metab | Group followed over time | 2026 |
| Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study.Aesthetic Plast Surg | Group followed over time | 2026 |
| Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.Diabetes Obes Metab | Group followed over time | 2026 |
| Short-term effect of tirzepatide on serum calcitonin in adults with obesity.Endocrine | Group followed over time | 2026 |
| Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.Diab Vasc Dis Res | Group followed over time | 2026 |
| Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study.Clin Nutr | Group followed over time | 2026 |
| GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.J Addict Med | Group followed over time | 2026 |
| Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice.Nutrients | Group followed over time | 2026 |
| Real-world prescribing patterns and early weight and blood pressure outcomes of GLP-1-based therapies: a retrospective observational study in the United Arab Emirates.BMC Endocr Disord | Group followed over time | 2026 |
| A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.Diabetes Obes Metab | Group followed over time | 2026 |
| Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study.Diabetes Obes Metab | Group followed over time | 2026 |
| Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).Diabetes Obes Metab | Group followed over time | 2026 |
| A real-world study of tirzepatide for weight loss in adults without diabetes mellitus.Int J Obes (Lond) | Group followed over time | 2026 |
| GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.J Pediatr Endocrinol Metab | Group followed over time | 2026 |
| Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.ESC Heart Fail | Group followed over time | 2026 |
| GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study.Br J Clin Pharmacol | Group followed over time | 2026 |
| Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study.J Diabetes Complications | Group followed over time | 2025 |
| Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.Diabetes Obes Metab | Group followed over time | 2025 |
| Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.Diabetes Care | Group followed over time | 2025 |
| Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study.Diabetes Res Clin Pract | Group followed over time | 2025 |
| Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.JAMA | Group followed over time | 2025 |
| Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study.JMIR Form Res | Group followed over time | 2025 |
| Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.Am J Ophthalmol | Group followed over time | 2025 |
| Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United States.Clin Ther | Group followed over time | 2025 |
| Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.JMIR Infodemiology | Group followed over time | 2025 |
| Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.Diabetes Obes Metab | Group followed over time | 2025 |
| Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?Diabetes Care | Group followed over time | 2025 |
| Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States.Diabetes Metab | Group followed over time | 2025 |
| Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.Diabetes Obes Metab | Group followed over time | 2025 |
| Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study.J Diabetes Sci Technol | Group followed over time | 2025 |
| Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.Dig Dis Sci | Group followed over time | 2024 |
| Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus.Diabetes Obes Metab | Group followed over time | 2024 |
| Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.JAMA Intern Med | Group followed over time | 2024 |
| Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like-Peptide-1 Use Following 10-Session Cognitive-Behavioural Therapy for Binge-Eating Disorder: A Single-Case Experimental Design.Eur Eat Disord Rev | Case reports | 2026 |
| Recurrent In-Stent Restenosis and Accelerated Neoatherosclerosis in a Middle-Aged Woman With High Inflammatory Burden.JACC Case Rep | Case reports | 2026 |
| GLP-1RA based treatment in patients with a PCSK1 mutation has profound effects on body weight - two case reports.Obes Facts | Case reports | 2026 |
| Tirzepatide-induced pneumatosis intestinalis: a rare but clinically significant gastrointestinal adverse effect.Am J Clin Pathol | Case reports | 2026 |
| Case Report: Panic attacks after tirzepatide injection in two female patients with recurrent depressive disorder.Front Drug Saf Regul | Case reports | 2026 |
| Non-ST Elevation Myocardial Infarction Following Significant Weight Loss During Tirzepatide Therapy: A Case Report.Cureus | Case reports | 2026 |
| Simultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series.JCEM Case Rep | Case reports | 2026 |
| Confluent and reticulated papillomatosis improvement with tirzepatide-associated weight loss: A case report.JAAD Case Rep | Case reports | 2026 |
| Tirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of 3 cases.JCEM Case Rep | Case reports | 2026 |
| Treatment-Induced Neuropathy Presenting as Thoracic Radiculopathy and Abdominal Wall Protrusion After Marked Glycemic Improvement With Tirzepatide.Cureus | Case reports | 2026 |
| Ischemic Colitis in the Setting of Tirzepatide Use: A Potentially Underrecognized Adverse Effect.Cureus | Case reports | 2026 |
| Duodenal Ulcer Perforation Following Tirzepatide Injections for Weight Loss Management: A Case Report.Cureus | Case reports | 2026 |
| Case report: Tirzepatide-responsive refractory diabetes mellitus in an adult female with prader-willi syndrome.Medicine (Baltimore) | Case reports | 2026 |
| Tirzepatide non-response with subsequent semaglutide response in class 2 obesity.JCEM Case Rep | Case reports | 2026 |
| Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.Obes Pillars | Case reports | 2026 |
| Exercise-induced anaphylaxis with a cofactor of GIP/GLP-1 receptor agonist: A case report.J Allergy Clin Immunol Glob | Case reports | 2026 |
| Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.Headache | Case reports | 2026 |
| Opioid Toxicity Associated With Tirzepatide in a Patient on Chronic Oral Morphine.Cureus | Case reports | 2026 |
| Case Report: Tirzepatide improves glycemic control in Rabson-Mendenhall syndrome.Front Endocrinol (Lausanne) | Case reports | 2026 |
| Tirzepatide as a possible trigger of bullous pemphigoid: A case report.J Dtsch Dermatol Ges | Case reports | 2026 |
| Clinical efficacy of tirzepatide for weight regain and suboptimal glycemic control following laparoscopic sleeve gastrectomy: a case series of three patients with obesity-associated type 2 diabetes.Front Endocrinol (Lausanne) | Case reports | 2026 |
| Tirzepatide-Based Therapy for Multidomain Metabolic Improvement in an Active Duty Service Member: A Case Report.Cureus | Case reports | 2026 |
| Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity Reactions.Cureus | Case reports | 2026 |
| Case report: Tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use.JAAD Case Rep | Case reports | 2026 |
| Papular granuloma annulare associated with tirzepatide: A case report.JAAD Case Rep | Case reports | 2026 |
| Tirzepatide-Associated Severe Hepatocellular Injury: A Case Report and Diagnostic Considerations.Diagnostics (Basel) | Case reports | 2026 |
| A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors.Cureus | Case reports | 2026 |
| When Weight Loss Turns Dangerous: A Case Report of Tirzepatide-Induced Ketoacidosis in a Non-diabetic Woman.Cureus | Case reports | 2026 |
| Severe Dumping and Persistent Obesity in a Post-Roux-en-Y Gastric Bypass Patient With a Non-discernible Gastric Pouch and Symptomatic Improvement on Tirzepatide: A Case Report.Cureus | Case reports | 2026 |
| Starvation-Type Euglycemic Ketoacidosis After Unsupervised Tirzepatide Use in a Non-Obese, Non-Diabetic Woman.Am J Case Rep | Case reports | 2026 |
| Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome.JCEM Case Rep | Case reports | 2026 |
| Glucagon-Like Peptide-1 Receptor Agonist and Hyponatremia: A Potential Association.JACC Case Rep | Case reports | 2026 |
| Combination of prolonged water fasting and GLP-1 for refractory morbid obesity: Case report.Eur J Clin Nutr | Case reports | 2026 |
| Endotypic Trait Responses to 12-Month Tirzepatide Treatment for an Obese Patient with Obstructive Sleep Apnea: A Case Report.Obes Facts | Case reports | 2026 |
| Possible Attenuation of Early Weight Loss During Tirzepatide Therapy in a Patient Treated With Levosulpiride: A Case Report and Mechanistic Hypothesis.Cureus | Case reports | 2026 |
| Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation.Front Endocrinol (Lausanne) | Case reports | 2026 |
| Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection.ACG Case Rep J | Case reports | 2026 |
| Acute Unilateral NAION following Tirzepatide Therapy: A Case Report.Case Rep Ophthalmol | Case reports | 2026 |
| Acute Small Bowel Obstruction Induced by Tirzepatide (Mounjaro).Cureus | Case reports | 2026 |
| Weight Drop-Foot Drop: A Case Series of Peroneal Nerve Palsy from Leg Crossing after Tirzepatide-Mediated Weight Loss.Case Rep Neurol | Case reports | 2026 |
| Biomimetic Hematoma Enables Healing in Complex Periprosthetic Fracture Nonunion with Multiple Comorbidities: A Case Report.JBJS Case Connect | Case reports | 2026 |
| Longitudinal 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) Findings in Korsakoff Syndrome After Rapid Weight Loss During Tirzepatide Therapy: A Case Report.Cureus | Case reports | 2026 |
| Tirzepatide-associated interstitial kidney injury.JCEM Case Rep | Case reports | 2026 |
| Facial nodules following filler injections after initiating compounded tirzepatide use.JAAD Case Rep | Case reports | 2026 |
| Complete Skin Remission of Lichen Planus With Tirzepatide.Australas J Dermatol | Case reports | 2026 |
| A Case of an Invisible Pancreatic Neuroendocrine Tumor Decoded by Endoscopic Ultrasound.Cureus | Case reports | 2026 |
| Targeted Ileal Bile Acid Transporter Inhibition as Rescue Therapy for Tirzepatide-Induced Severe Constipation: A Case Report.Case Rep Gastroenterol | Case reports | 2026 |
| Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series.Am J Case Rep | Case reports | 2026 |
| Brachial Plexopathy Following Rapid Weight Loss from Tirzepatide: A Case Report.Pain Med Case Rep | Case reports | 2026 |
| A Case of GLP-1 Receptor Agonist-Induced Dysphoria and Aggression in a Patient With Underlying Major Depressive Disorder.J Psychiatr Pract | Case reports | 2026 |
| Symmetrical drug-related intertriginous and flexural exanthema associated with tirzepatide.JAAD Case Rep | Case reports | 2026 |
| Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency.JCEM Case Rep | Case reports | 2026 |
| Rapid remission of Hailey-Hailey disease with tirzepatide therapy: A case report.JAAD Case Rep | Case reports | 2026 |
| Psoriasis flare following tirzepatide initiation in a patient with plaque psoriasis in remission: A case report.JAAD Case Rep | Case reports | 2026 |
| Hypercalcemia Induced by Tirzepatide and Calcium Supplementation: A Case Report.Cureus | Case reports | 2026 |
| A Massive Type IV Hiatal Hernia With Gastric Volvulus and the Complicated Road to Recovery.Cureus | Case reports | 2026 |
| Mixed Medullary and Papillary Thyroid Carcinoma in a Patient on Tirzepatide.Cureus | Case reports | 2026 |
| Severe Euglycemic Ketoacidosis Secondary to Tirzepatide Use for Weight Loss.Cureus | Case reports | 2026 |
| Thyroid Dysfunction Following Tirzepatide Use in a Post-thyroidectomy Patient on Stable Levothyroxine Therapy: A Case Study.Cureus | Case reports | 2026 |
| Ketoacidosis associated with tirzepatide use in a nonobese individual without diabetes.JCEM Case Rep | Case reports | 2026 |
| Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes.Arch Endocrinol Metab | Case reports | 2026 |
| Acute onset of neovascular age-related macular degeneration after initiation of tirzepatide.Diabetol Int | Case reports | 2026 |
| Drug-induced liver injury secondary to tirzepatide.BMJ Case Rep | Case reports | 2026 |
| Tirzepatide and Metformin Effects on Hunger and BMI in an Adolescent with Hyperphagia and Severe Obesity due to MC4R Deficiency: A Case Report.Obes Facts | Case reports | 2026 |
| Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity.Endocrinol Diabetes Metab Case Rep | Case reports | 2026 |
| Tirzepatide-Associated Euglycemic Diabetic Ketoacidosis in the Absence of Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.J Emerg Med | Case reports | 2026 |
| Acute liver injury associated with tirzepatide: An unexpected adverse event warranting clinical attention.Ann Endocrinol (Paris) | Case reports | 2026 |
| Upadacitinib-Induced Remission in Multicentric Reticulohistiocytosis: Expanding the Therapeutic Role of JAK Inhibition.Int J Mol Sci | Case reports | 2026 |
| Severe diabetic ketoacidosis associated with insulin dose reduction after tirzepatide initiation.BMJ Case Rep | Case reports | 2026 |
| Tirzepatide-Induced Liver Injury: A Rare Complication.AACE Endocrinol Diabetes | Case reports | 2026 |
| Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health.Urol Case Rep | Case reports | 2026 |
| Obesity medications and acquired hypothalamic obesity in adults: A two-case experience.Obes Pillars | Case reports | 2026 |
| Two Cases of Diabetes Remission through Temporary Tirzepatide Treatment.Intern Med | Case reports | 2026 |
| Vitreous hemorrhage in a patient on tirzepatide: Coincidence or drug induced?Oman J Ophthalmol | Case reports | 2026 |
| A Rare Case of Tirzepatide-Associated Immune Thrombocytopenia.Cureus | Case reports | 2026 |
| Probable Tirzepatide-Induced Rhabdomyolysis in an HIV-Positive Patient.Hosp Pharm | Case reports | 2026 |
| Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.Ment Health Clin | Case reports | 2026 |
| A Case of Euglycemic Diabetic Ketoacidosis With Tirzepatide Use and Severe Calorie Restriction.JCEM Case Rep | Case reports | 2026 |
| Delayed-Onset Amiodarone Induced Thyrotoxicosis After Glucagon-Like Peptide-1 Agonist-Related Weight Loss.JCEM Case Rep | Case reports | 2026 |
| RFX6 maturity-onset diabetes of the young: clinical considerations and novel use of tirzepatide.Endocrinol Diabetes Metab Case Rep | Case reports | 2026 |
| Ischemic Colitis Associated With Tirzepatide Therapy in a Young Female Patient: A Case Report.Cureus | Case reports | 2026 |
| Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women.AACE Endocrinol Diabetes | Case reports | 2026 |
| GLP-1 Receptor Agonist-Associated Slimmer's Palsy: Implications for the Peripheral Nerve Surgeon.Ann Plast Surg | Case reports | 2026 |
| Insulinoma Unmasked By Tirzepatide: A Rare Case of Postprandial Hypoglycemia In a Nondiabetic Patient.JCEM Case Rep | Case reports | 2026 |
| Benign small bowel pneumatosis intestinalis: report of a rare adverse effect of tirzepatide.Trauma Surg Acute Care Open | Case reports | 2025 |
| New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report.Cureus | Case reports | 2025 |
| Severe Small-Bowel Obstruction in a High-Risk Patient on Long-Term Tirzepatide Therapy: A Case Report.Cureus | Case reports | 2025 |
| Severe Adverse Effects of Tirzepatide Overdose Requiring Intensive Care Unit Admission and Complex Rehabilitation.Cureus | Case reports | 2025 |
| Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report.Am J Case Rep | Case reports | 2025 |
| Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide.Nat Med | Case reports | 2025 |
| Vicarious efficacy of tirzepatide in a cohabiting couple: An observational case report.Obes Pillars | Case reports | 2025 |
| Acute Deep Vein Thrombosis in the Setting of Tirzepatide Use: A Case Highlighting Emerging Concerns.JCEM Case Rep | Case reports | 2025 |
| Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures.JCEM Case Rep | Case reports | 2025 |
| First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss.Eur Arch Otorhinolaryngol | Case reports | 2025 |
| Intractable Vomiting in the Setting of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Cannabis Usage.Cureus | Case reports | 2025 |
| Redefining Cystic Fibrosis-Related Diabetes Management With Tirzepatide: A Case Report.Cureus | Case reports | 2025 |
| An Online Prescription for Hospitalisation: Euglycaemic Ketoacidosis Caused by an Online Tirzepatide Prescription.Cureus | Case reports | 2025 |
| Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome.J Clin Endocrinol Metab | Case reports | 2025 |
| Acute Mesenteric Ischemia as a Severe Complication Associated With Tirzepatide: A Case Report and Safety Alert.Cureus | Case reports | 2025 |
| Diverticular Stricture and Hepatic Abscess Formation During Tirzepatide Therapy for Obesity.Cureus | Case reports | 2025 |
| Efficacy and Safety of Tirzepatide in Refractory Hypoglycemia Associated with Esophagojejunostomy.JCEM Case Rep | Case reports | 2025 |
| Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.Eur J Clin Nutr | Case reports | 2025 |
| FDG PET/CT Images Demonstrating Subclinical Pancreatitis in a Patient on a GLP-1 Receptor Agonist.Clin Nucl Med | Case reports | 2025 |
| Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: A case report.Medicine (Baltimore) | Case reports | 2025 |
| Effect of Tirzepatide in an Adolescent With Early-Onset Obesity, Hyperphagia, and Type 2 Diabetes.Cureus | Case reports | 2025 |
| Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.SAGE Open Med Case Rep | Case reports | 2025 |
| Exacerbation of Postural Orthostatic Tachycardia Syndrome With Tirzepatide Prescribed for Weight Loss.JACC Case Rep | Case reports | 2025 |
| Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.Cureus | Case reports | 2025 |
| Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring.JCEM Case Rep | Case reports | 2025 |
| The use of tirzepatide to successfully treat persistent genital arousal disorder/genitopelvic dysesthesia: a case report.Sex Med | Case reports | 2025 |
| Tirzepatide associated autoimmune encephalitis: A case report.J Am Pharm Assoc (2003) | Case reports | 2025 |
| Nonmechanical Small Bowel Obstruction in a Patient on Zepbound Without a Surgical History: A Case Report.Cureus | Case reports | 2025 |
| Case Report: Rhabdomyolysis following initiation of tirzepatide.Front Pharmacol | Case reports | 2025 |
| Novel finding of pulmonary embolism following tirzepatide (Manjaro) use in a young adult without risk factors of venous thromboembolic events.BMJ Case Rep | Case reports | 2025 |
| Anorgasmia following initiation of GLP-1 agonist.Sex Med | Case reports | 2025 |
| Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.AACE Endocrinol Diabetes | Case reports | 2025 |
| Rhabdomyolysis triggered by initiation of tirzepatide.Diabetol Int | Case reports | 2025 |
| Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy.Obesity (Silver Spring) | Case reports | 2025 |
| When the Transition Goes Wrong: A Rare Case of Diabetic Ketoalkalosis After Transitioning to Tirzepatide in Insulin-dependent Type 2 Diabetes.Cureus | Case reports | 2025 |
| Tirzepatide Affect Sexual Function in Women: Case Report.Clin Med Insights Case Rep | Case reports | 2025 |
| Life-Threatening Ventricular Fibrillation Linked to High-Dose Tirzepatide-Induced Gastrointestinal Side Effects.Cureus | Case reports | 2025 |
| A Probable Case of Tirzepatide-Induced Acute Pancreatitis.Cureus | Case reports | 2025 |
| Fatal, Fulminant, Necrotizing Pancreatitis Associated With Recent Tirzepatide Initiation.JCEM Case Rep | Case reports | 2025 |
| Dual Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist-Associated Thyroiditis: A Case Report of Thyroid Dysfunction Following Tirzepatide Use.Cureus | Case reports | 2025 |
| Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide.Front Endocrinol (Lausanne) | Case reports | 2025 |
| Systemic Inflammatory Response Syndrome Following High-Dose Intravenous Glutathione-Containing Revitalising Solution in a Patient on Tirzepatide: A Case Report.Cureus | Case reports | 2025 |
| Tirzepatide-induced lichen planus pigmentosus.JAAD Case Rep | Case reports | 2025 |
| Successful Treatment of Hypothalamic Obesity with Tirzepatide.AACE Endocrinol Diabetes | Case reports | 2025 |
| Euglycemic Ketoacidosis in a Non-diabetic Patient After Tirzepatide Use: A Cautionary Tale.Cureus | Case reports | 2025 |
| Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect.ACG Case Rep J | Case reports | 2025 |
| Very-low-calorie-diet, tirzepatide, and bariatric surgery: a multidisciplinary success in super-super obesity.J Surg Case Rep | Case reports | 2025 |
| Patient With Tirzepatide-treated Type 2 Diabetes With Difficult Visualization During Esophagogastroduodenoscopy.JCEM Case Rep | Case reports | 2025 |
| Acute Duodenal Ulcer Perforation Following Tirzepatide Treatment: A Case Report.Cureus | Case reports | 2025 |
| A Case of Pulmonary Hemorrhage, Supratherapeutic International Normalized Ratio (INR), and Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: Unmasking a Potential Link to Tirzepatide.Cureus | Case reports | 2025 |
| Skeletal Muscle Mass and Body Weight Fall Proportionally With Use of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Tirzepatide: Case Report and Review of Literature.AACE Clin Case Rep | Case reports | 2025 |
| Treatment of obesity in spinal cord injury with tirzepatide: a case report.Spinal Cord Ser Cases | Case reports | 2025 |
| Euglycemic Ketoacidosis Following Coadministration of an SGLT2 Inhibitor and Tirzepatide.JCEM Case Rep | Case reports | 2025 |
| Expectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes - Case Presentations.J Diabetes Sci Technol | Case reports | 2025 |
| Appendicitis After Initiation of Tirzepatide.Diabetes Metab Syndr Obes | Case reports | 2025 |
| Acute Functional Gastric Outlet Obstruction Associated With Low-Dose Tirzepatide.Cureus | Case reports | 2025 |
| Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report.Cureus | Case reports | 2024 |
| Acute Pancreatitis Caused by Tirzepatide.Cureus | Case reports | 2024 |
| Exploring Hypoglycemic Ketoacidosis in Nondiabetic Patients on Tirzepatide: Is Starvation the Culprit?Am J Case Rep | Case reports | 2024 |
| Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series.Hosp Pharm | Case reports | 2024 |
| Effect of switching from dulaglutide to tirzepatide on blood glucose and renal function.Drug Discov Ther | Case reports | 2024 |
| Dramatic Changes in Thiopurine Metabolite Levels in a Patient With Inflammatory Bowel Disease Treated With Tirzepatide for Weight Loss.ACG Case Rep J | Case reports | 2024 |
| Tirzepatide-Associated Colonic Ischemia.ACG Case Rep J | Case reports | 2024 |
| Extensive Deep Vein Thrombosis in a Young Man Taking Tirzepatide for Weight Loss.AACE Clin Case Rep | Case reports | 2024 |
| Tirzepatide Improves Early Dumping Syndrome and Glucose Nadir in Postbariatric Hypoglycemia After Sleeve Gastrectomy.JCEM Case Rep | Case reports | 2024 |
| Food noise: A theoretical review.Appetite | Review of studies | 2027 |
| GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases.Eur J Pharmacol | Review of studies | 2026 |
| GLP-1 Receptor Agonists and Reproductive Health: Implications for Contraception, Fertility, and Pregnancy.Endocrinol Metab Clin North Am | Review of studies | 2026 |
| The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.J Diabetes Metab Disord | Review of studies | 2026 |
| GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific risk.N Am Spine Soc J | Review of studies | 2026 |
| One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.Appetite | Review of studies | 2026 |
| Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy.J Endocr Soc | Review of studies | 2026 |
| Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy.Maturitas | Review of studies | 2026 |
| Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications.Curr Opin Nephrol Hypertens | Review of studies | 2026 |
| From adiposity to multisystem morbidity: the case for weight loss as disease modification.Lancet Diabetes Endocrinol | Review of studies | 2026 |
| From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic framework.Curr Probl Cardiol | Review of studies | 2026 |
| Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations.Int Clin Psychopharmacol | Review of studies | 2026 |
| Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.Drugs | Review of studies | 2026 |
| Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses.Expert Opin Pharmacother | Review of studies | 2026 |
| GLP-1-Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection.Diabetes Obes Metab | Review of studies | 2026 |
| Interpreting Diabetic Retinal Outcomes After GLP-1 Receptor Agonist and Tirzepatide Initiation: Clinical Evidence and Its Limits.Diabetes Obes Metab | Review of studies | 2026 |
| Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity.Rambam Maimonides Med J | Review of studies | 2026 |
| The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome.Diabetes Metab Syndr Obes | Review of studies | 2026 |
| Pancreatic and Gallbladder Adverse Events Associated with Tirzepatide in Obesity Management: A Scoping Review.Diabetes Metab Syndr Obes | Review of studies | 2026 |
| GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications.Eur J Clin Pharmacol | Review of studies | 2026 |
| Beyond LDL-C: A case-based review of complex Dyslipidemia.Am J Med Sci | Review of studies | 2026 |
| How Well Are We Measuring Nausea? A Narrative Review of Patient-Reported Outcome Gaps in GLP-1 Receptor Agonist Obesity Trials.Diabetes Obes Metab | Review of studies | 2026 |
| Modern antidiabetic therapy in older adults with type 2 diabetes: evidence, best practice and a clinical pharmacist's framework.Expert Rev Clin Pharmacol | Review of studies | 2026 |
| Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search.Rev Endocr Metab Disord | Review of studies | 2026 |
| Chronic Intermittent Hypoxia and MASLD in Obstructive Sleep Apnea: A Critical Appraisal of Mechanistic and Causal Evidence.Int J Mol Sci | Review of studies | 2026 |
| Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies.Curr Obes Rep | Review of studies | 2026 |
| Incretin-based therapies in menopause: Current landscape.Maturitas | Review of studies | 2026 |
| GLP-1 Receptor Agonist Therapy in Patients with Cancer: A Review of Clinical Outcomes.Int J Mol Sci | Review of studies | 2026 |
| Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review.Front Endocrinol (Lausanne) | Review of studies | 2026 |
| Medical treatments for obesity: what does the future have in store?J Clin Endocrinol Metab | Review of studies | 2026 |
| Glucagon-Like Peptide-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From Rats to Humans.Biol Psychiatry | Review of studies | 2026 |
| Do Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.Aesthet Surg J | Review of studies | 2026 |
| Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation.Biol Psychiatry | Review of studies | 2026 |
| GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?Acta Diabetol | Review of studies | 2026 |
| Pharmacotherapy for MASLD/MASH: approved therapies, drug repurposing, and emerging mechanism-based candidates.Expert Opin Pharmacother | Review of studies | 2026 |
| From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.Front Pharmacol | Review of studies | 2026 |
| The evolving role of metabolic and bariatric surgery in contemporary clinical practice.Eur J Prev Cardiol | Review of studies | 2026 |
| Energy-Based Devices for GLP-1 Receptor Agonist-Associated Facial Aging: A Tissue-Specific Safety Framework.Clin Cosmet Investig Dermatol | Review of studies | 2026 |
| Cardiometabolic Substrate Modification in Atrial Fibrillation: Obesity and Epicardial Adipose Tissue in the Era of Incretin-Based Therapies and Catheter Ablation.J Cardiovasc Dev Dis | Review of studies | 2026 |
| Exploring semaglutide for alcohol use disorder: A review of clinical efficacy and neurobiological mechanisms.Addict Behav | Review of studies | 2026 |
| Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective.Pharmaceutics | Review of studies | 2026 |
| Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review.Metabolites | Review of studies | 2026 |
| Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review.Med Sci (Basel) | Review of studies | 2026 |
| Weight Management in Obesity-Associated Sleep-Disordered Breathing: Mechanisms, Clinical Management, and Emerging Therapies.Endocr Pract | Review of studies | 2026 |
| Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review.BMJ Med | Review of studies | 2026 |
| Bidirectional pharmacology of GIP receptor targeting in obesity: Historical foundations, mechanistic divergence, and translational boundaries.Peptides | Review of studies | 2026 |
| Perioperative management of patients taking GLP-1 receptor agonists: A comparative review of international clinical guidelines.Saudi J Anaesth | Review of studies | 2026 |
| Single or multiple nutritional hormone receptor modulators for chronic kidney disease.Clin Kidney J | Review of studies | 2026 |
| Beyond metabolic control: the potential role of antidiabetic therapies in modulating male reproductive function and spermatogenesis.Rev Endocr Metab Disord | Review of studies | 2026 |
| Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutr Clin Pract | Review of studies | 2026 |
| Effect of GLP-1 receptor agonist on nutrient intake: A narrative review.Nutr Clin Pract | Review of studies | 2026 |
| The Expanding Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agonists in Dermatology: From Immunometabolism to Clinical Practice.Dermatol Ther (Heidelb) | Review of studies | 2026 |
| A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy.Obes Sci Pract | Review of studies | 2026 |
| Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review.JAMA Otolaryngol Head Neck Surg | Review of studies | 2026 |
| Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Ann Intern Med | Review of studies | 2026 |
| Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society.Maturitas | Review of studies | 2026 |
| Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.Adv Ther | Review of studies | 2026 |
| GLP-1 receptor agonists in pediatric obesity.Dig Liver Dis | Review of studies | 2026 |
| Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective.Surg Obes Relat Dis | Review of studies | 2026 |
| Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities.Int J Eat Disord | Review of studies | 2026 |
| Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.Ann Otol Rhinol Laryngol | Review of studies | 2026 |
| What obgyns need to know about GLP-1 receptor agonists.Curr Opin Obstet Gynecol | Review of studies | 2026 |
| GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review.Int J Mol Sci | Review of studies | 2026 |
| GLP-1-Based therapies for obesity-related heart failure with preserved ejection fraction: an umbrella review incorporating broader heart failure and cardiometabolic evidence.Front Cardiovasc Med | Review of studies | 2026 |
| Glucagon-like Peptide-1-based and Emerging Cardiometabolic Therapies in Heart Failure with Preserved Ejection Fraction: Linking Molecular Mechanisms to Clinical Outcomes.Card Fail Rev | Review of studies | 2026 |
| Continuous glucose monitoring after discontinuation of incretin-based obesity pharmacotherapy: indirect evidence and a research framework for metabolic stability and weight maintenance.Front Endocrinol (Lausanne) | Review of studies | 2026 |
| Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the "Liver-Other Organs" Axes.Int J Mol Sci | Review of studies | 2026 |
| From Adipose Tissue Dysfunction to Venous Thromboembolism.J Clin Med | Review of studies | 2026 |
| Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists.Front Endocrinol (Lausanne) | Review of studies | 2026 |
| Incretin-Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency.Obesity (Silver Spring) | Review of studies | 2026 |
| Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery.Heart | Review of studies | 2026 |
| Tirzepatide for Weight Recurrence After Metabolic and Bariatric Surgery: A Critical Review of Direct and Indirect Evidence with Emphasis on Sleeve Gastrectomy, Nutritional Safety, and Clinical Implications.Nutrients | Review of studies | 2026 |
| Effects of Tirzepatide on Pancreatic β-Cell Function in Adults With Type 2 Diabetes Mellitus: A Systematic Review.Cureus | Review of studies | 2026 |
| GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework.J Clin Med | Review of studies | 2026 |
| Economic evaluations of antiobesity medications: A systematic literature review.Br J Clin Pharmacol | Review of studies | 2026 |
| Pancreatic-liver crosstalk, novel molecular mediators, and 2025 therapeutic breakthroughs.World J Methodol | Review of studies | 2026 |
| Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment.Ann Pharmacother | Review of studies | 2026 |
| De-escalating Therapy in Obstructive Sleep Apnoea After Glucagon-Like Peptide-1 Receptor Agonist-Induced Weight Loss: A Narrative Review.Cureus | Review of studies | 2026 |
| Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology.Front Cardiovasc Med | Review of studies | 2026 |
| Visceral Adiposity and Renal Health: From Pathophysiological Mechanisms to Novel Therapeutic Strategies.J Clin Med | Review of studies | 2026 |
| GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.Int J Mol Sci | Review of studies | 2026 |
| Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.Cureus | Review of studies | 2026 |
| The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care.Biomed J | Review of studies | 2026 |
| Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.Clin Oral Investig | Review of studies | 2026 |
| The Impact of Glucagon-Like Peptide-1 Receptor Agonist-Induced Nutritional Deficiencies on Skin Health: A Narrative Review With a Proposed Framework for the Aesthetic Practitioner.Aesthet Surg J Open Forum | Review of studies | 2026 |
| Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review.Int J Mol Sci | Review of studies | 2026 |
| Non-positive Airway Pressure Therapies for Obstructive Sleep Apnoea and Central Sleep Apnoea.Card Fail Rev | Review of studies | 2026 |
| Semaglutide and Tirzepatide for the Treatment of MASH: What Works, What is Coming, and What is Missing.Digestion | Review of studies | 2026 |
| Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.World J Clin Pediatr | Review of studies | 2026 |
| The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis.Nutr Metab Cardiovasc Dis | Review of studies | 2026 |
| GLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review.Biomol Biomed | Review of studies | 2026 |
| Incretin signaling suppresses high glucose-induced β-cell hypoxia through a cAMP/PKA-dependent mechanism.Biochem Biophys Res Commun | In animals | 2026 |
| Combination of genetic eNOS deficiency and high-fat diet induces reproducible cardiometabolic HFpEF.Redox Biol | In animals | 2026 |
| Semaglutide and Tirzepatide Suppress Hepatic Fatty Acid Uptake and Fatty Acid β-Oxidation in High-Fat Diet-Induced Obesity Mice.J Proteome Res | In animals | 2026 |
| Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.Nat Metab | In animals | 2026 |
| Increased energy expenditure through intermittent cold exposure does not enhance tirzepatide-induced weight loss in obese mice.Am J Physiol Regul Integr Comp Physiol | In animals | 2026 |
| Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.Tissue Cell | In animals | 2026 |
| A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.Diabetes Obes Metab | In animals | 2026 |
| Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease.Cell Rep Med | In animals | 2026 |
| Possible protective effects of tirzepatide on polycystic ovary syndrome in female rat model induced by testosterone propionate in comparison to metformin.Naunyn Schmiedebergs Arch Pharmacol | In animals | 2026 |
| Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine.ACS Chem Neurosci | In animals | 2026 |
| Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis.BMC Gastroenterol | In animals | 2026 |
| Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats.Hypertens Res | In animals | 2026 |
| Tirzepatide retention in iWAT with mesoporous polydopamine encapsulation enhances weight loss through leptin receptor signaling.J Adv Res | In animals | 2026 |
| Vascular remodelling in a mouse model of heart failure with preserved ejection fraction.J Physiol | In animals | 2026 |
| Tirzepatide attenuates neurotoxicity by suppressing inflammation, apoptosis and restoring neurotrophin expression in an Alzheimer's disease-like rat model.Metab Brain Dis | In animals | 2026 |
| The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.Front Endocrinol (Lausanne) | In animals | 2026 |
| Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.Psychopharmacology (Berl) | In animals | 2026 |
| Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice.Sci Rep | In animals | 2026 |
| Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents.EBioMedicine | In animals | 2026 |
| Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.Int J Obes (Lond) | In animals | 2026 |
| Tirzepatide attenuates estrogen deficiency-induced metabolic dysfunction-associated steatotic liver disease progression by reducing steatosis, inflammation, and fibrosis in obese-diabetic mice.Menopause | In animals | 2026 |
| Tirzepatide reduces intracellular lipid content by promoting the browning of white fat via the cAMP signaling pathway.Eur J Pharmacol | In animals | 2026 |
| Differential effects of the anti-obesity drug tirzepatide on adipose tissues: Brown fat as a key target.Biomed Pharmacother | In animals | 2026 |
| Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.EBioMedicine | In animals | 2026 |
| Tirzepatide counteracts brown adipose tissue whitening, inflammation, and mitochondrial dysfunction in estrogen-deficient obese diabetic mice.Life Sci | In animals | 2026 |
| Tirzepatide reverses hypothalamic inflammation, cellular stress, and neuropeptide imbalance in metabolic-menopausal dysfunction.Brain Res | In animals | 2026 |
| A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice.Diabetes Obes Metab | In animals | 2026 |
| Tirzepatide enhances liver structural integrity by promoting mitochondrial dynamics and mitophagy via PINK1/PRKN and SIRT3/NRF2 pathways in an obese-diabetic-menopausal mouse model.Tissue Cell | In animals | 2026 |
| Effect of Weight-Neutral Treatment With Semaglutide or Tirzepatide on β-Cell Identity in db/db Mice.Acta Physiol (Oxf) | In animals | 2026 |
| Development and validation of an LC-MS/MS method for Tirzepatide, a dual GIP/GLP-1 receptor agonist, in rat plasma for application to a pharmacokinetic study.J Chromatogr B Analyt Technol Biomed Life Sci | In animals | 2026 |
| A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity.Metabolism | In animals | 2026 |
| Tirzepatide improves neutrophilic inflammation in obese asthmatic mice by downregulating Th17 cell differentiation.Mol Biol Rep | In animals | 2025 |
| Comparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain.Arch Pharm Res | In animals | 2025 |
| Tirzepatide improves extracellular matrix integrity and vascularization in pancreatic islets of a mouse model of obesity, diabetes, and menopause.Biochem Biophys Res Commun | In animals | 2025 |
| Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice.J Clin Invest | In animals | 2025 |
| Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.Cardiovasc Res | In animals | 2025 |
| Assessing the therapeutic potential of Tirzepatide in modulating inflammatory responses and mitigating acute pancreatitis.Animal Model Exp Med | In animals | 2025 |
| The role of gut microbiota in Tirzepatide-mediated alleviation of high-fat diet-induced obesity.Eur J Pharmacol | In animals | 2025 |
| Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight.Mol Metab | In animals | 2025 |
| The dual GLP-1 and GIP receptor agonist tirzapetide provides an unintended interaction with the β-adrenoceptors and plays a role in glucose metabolism in hyperglycemic or senescent cardiac cells.Cardiovasc Diabetol | In animals | 2025 |
| Production of Fc-fused receptor agonists for glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) in the milk of transgenic mice.Transgenic Res | In animals | 2025 |
| Comparative Analysis of Pioglitazone and Tirzepatide on Body Weight, Glucose Levels, Neuroinflammation, and Oxidative Stress in Diabetic Rats.Drug Des Devel Ther | In animals | 2025 |
| Tirzepatide mitigates cognitive decline in zebrafish model of type 2 diabetes mellitus induced by high-fat diet.Naunyn Schmiedebergs Arch Pharmacol | In animals | 2025 |
| Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models.Sci Adv | In animals | 2025 |
| Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide.Cardiovasc Diabetol | In animals | 2025 |
| Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice.Diabetes Obes Metab | In animals | 2025 |
| Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss.Mol Metab | In animals | 2025 |
| Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice.Cardiovasc Res | In animals | 2025 |
| Dual GLP-1 and GIP Agonist Tirzepatide Exerted Neuroprotective Action in a Parkinson's Disease Rat Model.ACS Chem Neurosci | In animals | 2025 |
| Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis.Endocrine | In animals | 2025 |
| Tirzepatide alleviates oxidative stress and inflammation in diabetic nephropathy via IL-17 signaling pathway.Mol Cell Biochem | In animals | 2025 |
| Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), positively impacts the altered microbiota of obese, diabetic, ovariectomized mice.Life Sci | In animals | 2025 |
| Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics.Lipids Health Dis | In animals | 2025 |
| Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study.Int J Mol Sci | In animals | 2025 |
| Tirzepatide therapy counters inflammatory and apoptotic responses induced by high-fat diet in rat liver.Wiad Lek | In animals | 2025 |
| Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.Endocrine | In animals | 2025 |
| Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice.JCI Insight | In animals | 2024 |
| Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome, Implicating the Role of the AKT/GSK3β/NF-κB/NLRP3 Pathway.Int J Mol Sci | In animals | 2024 |
| Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer.Gynecol Oncol | In animals | 2024 |
| Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice.Diabetes Obes Metab | In animals | 2024 |
| Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling.Eur J Pharmacol | Other paper | 2026 |
| 12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study.Obes Pillars | Other paper | 2026 |
| Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran.J Diabetes Metab Disord | Other paper | 2026 |
| Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort.Clin Obes | Other paper | 2026 |
| Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.J Diabetes Metab Disord | Other paper | 2026 |
| Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.Obes Pillars | Other paper | 2026 |
| Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic program.Am J Prev Cardiol | Other paper | 2026 |
| Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis.J Diabetes Metab Disord | Other paper | 2026 |
| Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network.Pulmonology | Other paper | 2026 |
| Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.J Med Econ | Other paper | 2026 |
| Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.J Med Econ | Other paper | 2026 |
| Tirzepatide attenuates cardiac microvascular injury and ferroptosis-related lipid peroxidation in diabetic mice: endothelial responses in the context of partial PRKN silencing.Eur J Pharmacol | Other paper | 2026 |
| Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort.Hum Psychopharmacol | Other paper | 2026 |
| Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.Obesity (Silver Spring) | Other paper | 2026 |
| Adjuvant Glucagon-Like Peptide-1 Receptor Agonist Therapy Post-Bariatric Surgery: An Exploratory Single-Institution Analysis.J Surg Res | Other paper | 2026 |
| GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics.Diabetes Obes Metab | Other paper | 2026 |
| Brca1 heterozygosity leads to hepatic steatosis in male and female mice despite sexually dimorphic effects on systemic metabolism.Metabolism | Other paper | 2026 |
| Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.Diabetes Obes Metab | Other paper | 2026 |
| Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.Diabetes Obes Metab | Other paper | 2026 |
| Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.Dig Dis Sci | Other paper | 2026 |
| Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report.J Clin Psychopharmacol | Other paper | 2026 |
| A Subphenotype of Obesity With Reduced Enteroendocrine Glucagon-Like Peptide 1 Synthesis and Enhanced Tirzepatide Response.Gastroenterology | Other paper | 2026 |
| Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.Am J Surg | Other paper | 2026 |
| Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.Lancet Diabetes Endocrinol | Other paper | 2026 |
| Glucagon-Like Peptide-1 Analog-Type Amyloidosis: A Case Report and Review of the Literature.Am J Dermatopathol | Other paper | 2026 |
| Combined time-restricted feeding and resistance training enhance tirzepatide-induced improvements in adiposity and whole-body insulin sensitivity in female mice.J Physiol | Other paper | 2026 |
| Early Treatment Trajectory and Long-Term Persistence to Semaglutide for Obesity: A Population-Based Cohort Study.Diabetes Obes Metab | Other paper | 2026 |
| Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS.Endocrine | Other paper | 2026 |
| Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12-Month Real-World Results.Diabetes Obes Metab | Other paper | 2026 |
| Oral Health-Related Adverse Events of GLP-1 Receptor Agonists.JDR Clin Trans Res | Other paper | 2026 |
| Glucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study.Transplantation | Other paper | 2026 |
| Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis.Heart Rhythm | Other paper | 2026 |
| GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis.Breast Cancer Res Treat | Other paper | 2026 |
| Characteristics and Treatment Utilisation Patterns of Individuals Using Tirzepatide for Type 2 Diabetes in Germany.Adv Ther | Other paper | 2026 |
| Real-world effectiveness of tirzepatide among youth with type 2 diabetes and/or obesity: a multicenter analysis.J Pediatr Endocrinol Metab | Other paper | 2026 |
| Incretin-based therapies in psychiatry: A landscape analysis of ongoing randomized trials registered on ClinicalTrials.gov.J Psychiatr Res | Other paper | 2026 |
| Dual GIP/GLP-1 receptor agonist versus selective GLP-1 receptor agonist in patients undergoing primary total knee or hip arthroplasty.Eur J Orthop Surg Traumatol | Other paper | 2026 |
| Oral Versus Injectable Incretin-Based Anti-Obesity Therapies: An Integrated Computational and Evidence-Based Comparison of Orforglipron, Semaglutide, and Tirzepatide.OMICS | Other paper | 2026 |
| Adverse oral effects of GLP-1 and GIP receptor agonists: a scoping review protocol.BMJ Open | Other paper | 2026 |
| Tirzepatide for Obstructive Sleep Apnea: Trial Evidence, Cardiometabolic Effects, and Implications for Cardiovascular Practice.Cardiol Rev | Other paper | 2026 |
| Glucagon-Like Peptide-1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity.J Am Heart Assoc | Other paper | 2026 |
| Estimating the population eligible for Medicare's obesity-coverage demonstration.Health Aff Sch | Other paper | 2026 |
| Tirzepatide Attenuates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension: Association with the SIRT1/H4K12la/c-Jun Axis.Cells | Other paper | 2026 |
| Diabetic Retinal Disease Onset and Progression During Established Semaglutide or Tirzepatide Treatment: A Retrospective Comparative Cohort Study With a Descriptive Regional Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Review.Cureus | Other paper | 2026 |
| Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide.Diabet Med | Other paper | 2026 |
| Tirzepatide-Associated Lithium Toxicity: A Case Report.J Clin Psychopharmacol | Other paper | 2026 |
| GLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study.Int J Cardiol | Other paper | 2026 |
| Pregnancy and perinatal outcomes following exposure to GLP-1 and dual GLP-1/GIP receptor agonists: a time-window-stratified systematic review and meta-analysis.Front Pharmacol | Other paper | 2026 |
| Urinary Stone Recurrence After Initiation of GLP-1-Based Therapy: A Romanian Retrospective Cohort Study of Clinical, Renal, and Hydration-Related Factors.J Clin Med | Other paper | 2026 |
| Biliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors.J Clin Med | Other paper | 2026 |
| Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women.Nat Med | Other paper | 2026 |
| Weight-Loss Magnitude, Fat Mass, and Device-Estimated Muscle Mass Loss During Obesity Pharmacotherapy.J Clin Med | Other paper | 2026 |
| A Retrospective Chart Review of Tirzepatide and Semaglutide Use in Prediabetes Management and Cardiometabolic Outcomes in a Rural Primary Care Setting.J Dr Nurs Pract | Other paper | 2026 |
| Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort.Endocr Pract | Other paper | 2026 |